EP0198026B1
(en)
|
1984-10-04 |
1993-08-04 |
Sandoz Ag |
Monoclonal antibodies to cyclosporings
|
EP0194972B1
(en)
|
1985-03-11 |
1992-07-29 |
Sandoz Ag |
Novel cyclosporins
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
DE69013742T2
(de)
|
1989-04-15 |
1995-03-23 |
Nippon Chemiphar Co |
Peptide und diese Peptide enthaltende Wirkstoffe gegen Dementia.
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5409930A
(en)
|
1991-05-10 |
1995-04-25 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
GB9300059D0
(en)
|
1992-01-20 |
1993-03-03 |
Zeneca Ltd |
Quinazoline derivatives
|
ES2089723T3
(es)
|
1992-03-27 |
1996-10-01 |
American Home Prod |
29-demetoxirapamicina para inducir la inmunodepresion.
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
DE4221054A1
(de)
|
1992-06-30 |
1994-01-05 |
Herbst Bremer Goldschlaegerei |
Präparat zur prophylaktischen und therapeutischen Behandlung von Karies sowie Verfahren zum Herstellen desselben
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
DK0669929T3
(da)
|
1992-11-13 |
2007-01-29 |
Immunex Corp |
Elk-ligand, et cytokin
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
AU678058B2
(en)
|
1993-09-20 |
1997-05-15 |
John Innes Centre |
Recombinant production of novel polyketides
|
EP0672035A1
(en)
|
1993-10-01 |
1995-09-20 |
Novartis AG |
Pyrimidineamine derivatives and processes for the preparation thereof
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
WO1995014023A1
(en)
|
1993-11-19 |
1995-05-26 |
Abbott Laboratories |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
SG64372A1
(en)
|
1993-12-17 |
1999-04-27 |
Novartis Ag |
Rapamycin derivatives
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
WO1995024190A2
(en)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
IL112873A
(en)
|
1994-03-08 |
2005-03-20 |
Wyeth Corp |
Rapamycin-fkbp12 binding proteins, their isolation and their use
|
WO1995028484A1
(en)
|
1994-04-15 |
1995-10-26 |
Amgen Inc. |
Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
|
EP0682027B1
(de)
|
1994-05-03 |
1997-10-15 |
Novartis AG |
Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
|
GB9410142D0
(en)
|
1994-05-20 |
1994-07-06 |
Univ Warwick |
Carbapenems
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
GB9524630D0
(en)
|
1994-12-24 |
1996-01-31 |
Zeneca Ltd |
Chemical compounds
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
EP0817775B1
(en)
|
1995-03-30 |
2001-09-12 |
Pfizer Inc. |
Quinazoline derivatives
|
DE69609602T2
(de)
|
1995-04-03 |
2001-04-12 |
Novartis Ag |
Pyrazolderivate und verfahren zu deren herstellung
|
PT821671E
(pt)
|
1995-04-20 |
2001-04-30 |
Pfizer |
Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
WO1996041807A1
(en)
|
1995-06-09 |
1996-12-27 |
Novartis Ag |
Rapamycin derivatives
|
US5624677A
(en)
|
1995-06-13 |
1997-04-29 |
Pentech Pharmaceuticals, Inc. |
Controlled release of drugs delivered by sublingual or buccal administration
|
US6124453A
(en)
|
1995-07-04 |
2000-09-26 |
Novartis Ag |
Macrolides
|
KR100437582B1
(ko)
|
1995-07-06 |
2004-12-17 |
노파르티스 아게 |
피롤로피리미딘및그들의제조방법
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
DE69624081T2
(de)
|
1995-12-20 |
2003-06-12 |
Hoffmann La Roche |
Matrix-metalloprotease Inhibitoren
|
AU1441497A
(en)
|
1996-01-23 |
1997-08-20 |
Novartis Ag |
Pyrrolopyrimidines and processes for their preparation
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
CN1079796C
(zh)
|
1996-03-15 |
2002-02-27 |
诺瓦提斯公司 |
新的N-7-杂环基-吡咯并[2,3-d]嘧啶及其应用
|
DK0892789T4
(da)
|
1996-04-12 |
2010-04-06 |
Warner Lambert Co |
Irreversible inhibitorer af tyrosin kinaser
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
WO1997049688A1
(en)
|
1996-06-24 |
1997-12-31 |
Pfizer Inc. |
Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
|
JP2000511063A
(ja)
|
1996-07-05 |
2000-08-29 |
バイオティカ テクノロジー リミティド |
ポリケチド類及びそれらの合成
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
AU735648B2
(en)
|
1996-07-12 |
2001-07-12 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
ID19609A
(id)
|
1996-07-13 |
1998-07-23 |
Glaxo Group Ltd |
Senyawa-senyawa heterosiklik
|
DE69718472T2
(de)
|
1996-07-13 |
2003-11-06 |
Glaxo Group Ltd |
Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
TR199900066T2
(xx)
|
1996-07-18 |
1999-04-21 |
Pfizer Inc. |
Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
|
DE69738749D1
(de)
|
1996-08-16 |
2008-07-17 |
Schering Corp |
Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
TR199900387T2
(xx)
|
1996-08-23 |
1999-04-21 |
Pfizer Inc. |
Arils�lfonilamino hidroksamik asit t�revleri.
|
WO1998007726A1
(en)
|
1996-08-23 |
1998-02-26 |
Novartis Ag |
Substituted pyrrolopyrimidines and processes for their preparation
|
SE9603465D0
(sv)
|
1996-09-23 |
1996-09-23 |
Astra Ab |
New compounds
|
EP0929553B1
(en)
|
1996-10-02 |
2005-03-16 |
Novartis AG |
Pyrimidine derivatives and processes for the preparation thereof
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
AU4779897A
(en)
|
1996-10-02 |
1998-04-24 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
CA2277100C
(en)
|
1997-01-06 |
2005-11-22 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
EA002594B1
(ru)
|
1997-02-03 |
2002-06-27 |
Пфайзер Продактс Инк. |
Производные арилсульфониламиногидроксамовой кислоты
|
KR20000070751A
(ko)
|
1997-02-05 |
2000-11-25 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
세포 증식 억제제로서의 피리도[2,3-d]피리미딘 및 4-아미노피리미딘
|
AU5493598A
(en)
|
1997-02-07 |
1998-08-26 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
CN1247531A
(zh)
|
1997-02-11 |
2000-03-15 |
辉瑞大药厂 |
芳基磺酰基异羟肟酸衍生物
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6902913B2
(en)
|
1997-04-30 |
2005-06-07 |
Kosan Biosciences, Inc. |
Recombinant narbonolide polyketide synthase
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
WO1999007701A1
(en)
|
1997-08-05 |
1999-02-18 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
PT1003720E
(pt)
|
1997-08-08 |
2004-07-30 |
Pfizer Prod Inc |
Derivados de acido ariloxiarilsulfonilamino hidroxamico
|
WO2000012089A1
(en)
|
1998-08-31 |
2000-03-09 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
EP1025228A4
(en)
|
1997-10-21 |
2002-09-18 |
Human Genome Sciences Inc |
HUMAN PROTEIN TR11, TR11SV1 AND TR11SV2 SIMILAR TO THE TUMOR NECROSIS FACTOR RECEPTOR
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
US6153383A
(en)
|
1997-12-09 |
2000-11-28 |
Verdine; Gregory L. |
Synthetic transcriptional modulators and uses thereof
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
AU2591599A
(en)
|
1998-02-09 |
1999-08-23 |
Genentech Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
WO1999045009A1
(en)
|
1998-03-04 |
1999-09-10 |
Bristol-Myers Squibb Company |
Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
ES2347027T3
(es)
|
1998-05-22 |
2010-10-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Moleculas bifuncionales y terapias basadas en las mismas.
|
CA2314156C
(en)
|
1998-05-29 |
2010-05-25 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
JP2002520324A
(ja)
|
1998-07-10 |
2002-07-09 |
メルク エンド カムパニー インコーポレーテッド |
新規な血管形成インヒビター
|
IL142165A0
(en)
|
1998-10-02 |
2002-03-10 |
Kosan Biosciences Inc |
Polyketide synthase enzymes and recombinant dna constructs therefor
|
US6686454B1
(en)
|
1998-10-09 |
2004-02-03 |
Isotechnika, Inc. |
Antibodies to specific regions of cyclosporine related compounds
|
PT1004578E
(pt)
|
1998-11-05 |
2004-06-30 |
Pfizer Prod Inc |
Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
|
CA2359801A1
(en)
|
1999-02-09 |
2000-08-17 |
Rajesh S. Gokhale |
Methods to mediate polyketide synthase module effectiveness
|
PT1165085E
(pt)
|
1999-03-30 |
2006-10-31 |
Novartis Ag |
Derivados de ftalazina para tratar doencas inflamatorias
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
ATE324444T1
(de)
|
1999-06-07 |
2006-05-15 |
Immunex Corp |
Tek-antagonisten
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
PT1196186E
(pt)
|
1999-07-12 |
2008-02-14 |
Genentech Inc |
Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral.
|
AU783158B2
(en)
|
1999-08-24 |
2005-09-29 |
Ariad Pharmaceuticals, Inc. |
28-epirapalogs
|
ATE398120T1
(de)
|
1999-11-05 |
2008-07-15 |
Astrazeneca Ab |
Neue quinazolin-derivate
|
GB9927191D0
(en)
|
1999-11-17 |
2000-01-12 |
Angeletti P Ist Richerche Bio |
Methods and means for regulation of gene expression
|
US7220552B1
(en)
|
1999-11-19 |
2007-05-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and their use in the disruption of protein-protein interactions
|
WO2001036612A1
(en)
|
1999-11-19 |
2001-05-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and their use in the disruption of protein-protein interactions
|
EP1233943B1
(en)
|
1999-11-24 |
2011-06-29 |
Sugen, Inc. |
Ionizable indolinone derivatives and their use as ptk ligands
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
AU784995B2
(en)
|
2000-02-08 |
2006-08-17 |
Sinvent As |
Novel genes encoding a nystatin polyketide synthase and their manipulation and utility
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
DE60130435T2
(de)
|
2000-02-24 |
2009-07-23 |
Invitrogen Corp., Carlsbad |
Gleichzeitige stimulation und konzentration von zellen
|
ATE358718T1
(de)
|
2000-02-25 |
2007-04-15 |
Immunex Corp |
Integrin antagonisten
|
TR200200767T1
(tr)
|
2000-05-23 |
2002-09-23 |
Vertex Pharmaceuticals Incorporated |
Kaspaz engelleyiciler ve kullanımları
|
US7176037B2
(en)
|
2000-07-13 |
2007-02-13 |
The Scripps Research Institute |
Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
US7105530B2
(en)
|
2000-12-21 |
2006-09-12 |
Smithkline Beecham Corporation |
Pyrimidineamines as angiogenesis modulators
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US20030153053A1
(en)
|
2001-08-06 |
2003-08-14 |
Ralph Reid |
Methods for altering polyketide synthase genes
|
US6809077B2
(en)
|
2001-10-12 |
2004-10-26 |
Enanta Pharmaceuticals, Inc. |
Cyclosporin analogs for the treatment of autoimmune diseases
|
US6987090B2
(en)
|
2002-05-09 |
2006-01-17 |
Lg Household & Health Care Ltd. |
Use of 3-position cyclosporin derivatives for hair growth
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
US7012065B2
(en)
|
2003-02-07 |
2006-03-14 |
Enanta Pharmaceuticals, Inc. |
Cyclosporins for the treatment of immune disorders
|
EP1477563A3
(en)
|
2003-05-16 |
2004-11-24 |
Wyeth |
Cloning genes from streptomyces cyaneogriseus subsp.noncyanogenus for biosynthesis of antibiotics and methods of use
|
AU2004244626A1
(en)
|
2003-05-23 |
2004-12-09 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
|
WO2005005434A1
(en)
|
2003-07-08 |
2005-01-20 |
Novartis Ag |
Use of rapamycin and rapamycin derivatives for the treatment of bone loss
|
WO2005007190A1
(en)
|
2003-07-11 |
2005-01-27 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
WO2005016252A2
(en)
|
2003-07-11 |
2005-02-24 |
Ariad Gene Therapeutics, Inc. |
Phosphorus-containing macrocycles
|
AR045134A1
(es)
|
2003-07-29 |
2005-10-19 |
Smithkline Beecham Plc |
Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
|
EP1660458B1
(en)
|
2003-08-15 |
2012-01-25 |
Novartis AG |
2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
|
WO2005055808A2
(en)
|
2003-12-02 |
2005-06-23 |
Genzyme Corporation |
Compositions and methods to diagnose and treat lung cancer
|
WO2005094314A2
(en)
|
2004-03-26 |
2005-10-13 |
The Burnham Institute |
Modulators of shp2 tyrosine phosphatase and their use in the treatment of body weight disorders
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
US20060002932A1
(en)
|
2004-06-04 |
2006-01-05 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
ES2341351T3
(es)
|
2004-08-26 |
2010-06-18 |
Pfizer, Inc. |
Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina cinasas.
|
US7666901B2
(en)
|
2004-10-13 |
2010-02-23 |
Wyeth |
Analogs of 17-hydroxywortmannin as PI3K inhibitors
|
EP2343320B1
(en)
|
2005-03-25 |
2017-10-25 |
GITR, Inc. |
Anti-gitr antibodies and uses thereof
|
ES2427646T5
(es)
|
2005-05-09 |
2017-08-22 |
Ono Pharmaceutical Co., Ltd. |
Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
CA2622870A1
(en)
|
2005-09-20 |
2007-03-29 |
Pfizer Products Inc. |
Dosage forms and methods of treatment using a tyrosine kinase inhibitor
|
WO2007133822A1
(en)
|
2006-01-19 |
2007-11-22 |
Genzyme Corporation |
Gitr antibodies for the treatment of cancer
|
US8653238B2
(en)
|
2006-02-27 |
2014-02-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for transport of molecules with enhanced release properties across biological barriers
|
US20070203168A1
(en)
|
2006-02-28 |
2007-08-30 |
Zhao Jonathon Z |
Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
|
US8987474B2
(en)
|
2006-04-07 |
2015-03-24 |
University Of South Florida |
Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs
|
US7601852B2
(en)
|
2006-05-11 |
2009-10-13 |
Kosan Biosciences Incorporated |
Macrocyclic kinase inhibitors
|
JP5284977B2
(ja)
|
2006-12-07 |
2013-09-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法
|
WO2008124815A1
(en)
|
2007-04-10 |
2008-10-16 |
University Of South Florida |
Method of activating nk cells
|
JP5932217B2
(ja)
|
2007-07-12 |
2016-06-08 |
ジーアイティーアール, インコーポレイテッド |
Gitr結合分子を使用する併用療法
|
US8247397B2
(en)
|
2007-09-12 |
2012-08-21 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
WO2009049098A2
(en)
|
2007-10-09 |
2009-04-16 |
Indiana University Research & Technology Corporation |
Materials and methods for regulating the activity of phosphatases
|
JP5348725B2
(ja)
|
2007-10-25 |
2013-11-20 |
ジェネンテック, インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
KR100945483B1
(ko)
|
2007-10-25 |
2010-03-05 |
이화여자대학교 산학협력단 |
pikD 조절유전자의 발현벡터를 이용한 스트렙토미세스베네주엘라에(Streptomycesvenezuelae)에서폴리케타이드(polyketide)의 생산성 증가방법
|
GB0805363D0
(en)
|
2008-03-20 |
2008-04-30 |
Sinvent As |
Novel NRPS-PKS gene cluster and its manipulation and utility
|
WO2009135000A2
(en)
|
2008-04-30 |
2009-11-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs
|
WO2010003118A1
(en)
|
2008-07-02 |
2010-01-07 |
Trubion Pharmaceuticals, Inc. |
Tgf-b antagonist multi-target binding proteins
|
WO2010011666A2
(en)
|
2008-07-21 |
2010-01-28 |
University Of South Florida |
Indoline scaffold shp-2 inhibitors and cancer treatment method
|
US8586023B2
(en)
|
2008-09-12 |
2013-11-19 |
Mie University |
Cell capable of expressing exogenous GITR ligand
|
US20110171219A1
(en)
|
2008-09-19 |
2011-07-14 |
Fahar Merchant |
Treating cancer stem cells using targeted cargo proteins
|
JP5789190B2
(ja)
|
2008-09-24 |
2015-10-07 |
シャンハイ インスティテュート オブ オーガニック ケミストリー,チャイニーズ アカデミー オブ サイエンシズ |
新規の遺伝子クラスター
|
CN102365094A
(zh)
|
2009-01-30 |
2012-02-29 |
英安塔制药有限公司 |
用于预防或者治疗肝炎感染的环孢菌素类似物
|
WO2010121212A2
(en)
|
2009-04-17 |
2010-10-21 |
H. Lee Moffit Cancer Center And Research Institute, Inc. |
Indoline scaffold shp-2 inhibitors and method of treating cancer
|
US9163330B2
(en)
|
2009-07-13 |
2015-10-20 |
President And Fellows Of Harvard College |
Bifunctional stapled polypeptides and uses thereof
|
EP2456777A2
(en)
|
2009-07-24 |
2012-05-30 |
Université Henri Poincaré - Nancy 1 |
Stambomycin and derivatives, their production and their use as drugs
|
CA2771190C
(en)
|
2009-08-17 |
2020-01-21 |
Memorial Sloan-Kettering Cancer Center |
Heat shock protein binding compounds, compositions, and methods for making and using same
|
EP2473531A4
(en)
|
2009-09-03 |
2013-05-01 |
Merck Sharp & Dohme |
ANTI-GITRANT ANTIBODIES
|
JP2013505300A
(ja)
|
2009-09-22 |
2013-02-14 |
エルロン・セラピューティクス・インコーポレイテッド |
ペプチド模倣大環状分子
|
EP2492344B1
(en)
|
2009-10-22 |
2016-04-06 |
PeptiDream Inc. |
Rapid display method in translational synthesis of peptide
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
AU2010343057B2
(en)
|
2009-12-29 |
2017-02-23 |
Aptevo Research And Development Llc |
Heterodimer binding proteins and uses thereof
|
US8637684B2
(en)
|
2010-05-12 |
2014-01-28 |
Wisconsin Alumni Research Foundation |
Tautomycetin and tautomycetin analog biosynthesis
|
WO2012041524A1
(en)
|
2010-10-01 |
2012-04-05 |
Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) |
Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors
|
AU2011336727B2
(en)
|
2010-11-30 |
2016-11-03 |
The Johns Hopkins University |
Hybrid cyclic libraries and screens thereof
|
AR084217A1
(es)
|
2010-12-10 |
2013-05-02 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
US9428845B1
(en)
|
2010-12-28 |
2016-08-30 |
Warp Drive Bio, Inc. |
Identifying new therapeutic agents
|
CA2830516C
(en)
|
2011-03-23 |
2017-01-24 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
CN103748099B
(zh)
|
2011-05-19 |
2016-08-17 |
卡洛斯三世国家癌症研究中心基金会 |
作为蛋白激酶抑制剂的大环化合物
|
WO2012174489A2
(en)
|
2011-06-15 |
2012-12-20 |
The Ohio State University |
Small molecule composite surfaces as inhibitors of protein-protein interactions
|
TW201311689A
(zh)
|
2011-08-05 |
2013-03-16 |
必治妥美雅史谷比公司 |
作為因子xia抑制劑之新穎巨環化合物
|
DE102011111991A1
(de)
|
2011-08-30 |
2013-02-28 |
Lead Discovery Center Gmbh |
Neue Cyclosporin-Derivate
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
SI2861604T1
(sl)
|
2012-06-08 |
2017-05-31 |
Gilead Sciences, Inc. |
Makrociklični inhibitorji flavivirusov
|
NZ703066A
(en)
*
|
2012-06-08 |
2016-10-28 |
Gilead Sciences Inc |
Macrocyclic inhibitors of flaviviridae viruses
|
AR091279A1
(es)
|
2012-06-08 |
2015-01-21 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
ES2939836T3
(es)
|
2012-07-12 |
2023-04-27 |
Hangzhou Dac Biotech Co Ltd |
Conjugados de moléculas de unión celular con agentes citotóxicos
|
EP2922818B1
(en)
|
2012-11-24 |
2018-09-05 |
Hangzhou Dac Biotech Co., Ltd |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
WO2014113584A1
(en)
|
2013-01-16 |
2014-07-24 |
Rhode Island Hospital |
Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
WO2014152588A1
(en)
|
2013-03-15 |
2014-09-25 |
Araxes Pharma Llc |
Covalent inhibitors of kras g12c
|
EP3514178A1
(en)
|
2013-03-15 |
2019-07-24 |
Novartis AG |
Antibody drug conjugates
|
CN105142634B
(zh)
|
2013-04-26 |
2020-06-12 |
美国印第安纳大学研究和技术公司 |
包含Src同源-2结构域的致癌性蛋白酪氨酸磷酸酶-2(SHP2)的基于羟基吲哚羧酸的抑制剂
|
EP2806274A1
(en)
|
2013-05-24 |
2014-11-26 |
AIT Austrian Institute of Technology GmbH |
Lung cancer diagnostic method and means
|
WO2015003094A2
(en)
|
2013-07-03 |
2015-01-08 |
Indiana University Research & Technology Corporation |
Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors
|
EP2826586A1
(en)
|
2013-07-18 |
2015-01-21 |
Siemens Aktiengesellschaft |
A method and a system for machining an object
|
UA119971C2
(uk)
|
2013-10-10 |
2019-09-10 |
Араксіс Фарма Ллк |
Інгібітори g12c kras
|
ES2699351T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
|
CN105899493B
(zh)
|
2014-01-17 |
2019-03-29 |
诺华股份有限公司 |
用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
|
US10233431B2
(en)
|
2014-02-26 |
2019-03-19 |
The Regents Of The University Of California |
Producing 3-hydroxycarboxylic acid and ketone using polyketide synthases
|
EP3114483A1
(en)
|
2014-03-03 |
2017-01-11 |
Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. |
Method and device for detection of pseudomonas aeruginosa
|
JO3474B1
(ar)
*
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
AR102094A1
(es)
|
2014-09-25 |
2017-02-01 |
Araxes Pharma Llc |
Inhibidores de proteínas kras con una mutación g12c
|
TW201629069A
(zh)
|
2015-01-09 |
2016-08-16 |
霍普驅動生物科技股份有限公司 |
參與協同結合之化合物及其用途
|
EP3247378B8
(en)
|
2015-01-09 |
2023-08-23 |
Revolution Medicines, Inc. |
Macrocyclic compounds that participate in cooperative binding and medical uses thereof
|
WO2016160362A1
(en)
|
2015-03-31 |
2016-10-06 |
Allergan, Inc. |
Cyclosporins modified on the mebmt sidechain by heterocyclic rings
|
EA201792214A1
(ru)
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
Соединения замещенного хиназолина
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
WO2016191328A1
(en)
|
2015-05-22 |
2016-12-01 |
Allosta Pharmaceuticals |
Methods to prepare and employ binding site models for modulation of phosphatase activity and selectivity determination
|
US10494332B2
(en)
|
2015-06-01 |
2019-12-03 |
Indiana University Research And Technology Corporation |
Protein tyrosine phosphatases or SHP2 inhibitors and uses thereof
|
US10975080B2
(en)
|
2015-06-19 |
2021-04-13 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
EP3310774B1
(en)
|
2015-06-19 |
2020-04-29 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
EP3310771B1
(en)
|
2015-06-19 |
2020-07-22 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
EP3325447A1
(en)
|
2015-07-22 |
2018-05-30 |
Araxes Pharma LLC |
Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
JP7411326B2
(ja)
|
2015-10-01 |
2024-01-11 |
ワープ ドライブ バイオ インコーポレイテッド |
タンパク質-タンパク質インターフェースを分析するための方法および試薬
|
WO2017078499A2
(ko)
|
2015-11-06 |
2017-05-11 |
경북대학교 산학협력단 |
단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
|
WO2017079723A1
(en)
|
2015-11-07 |
2017-05-11 |
Board Of Regents, The University Of Texas System |
Targeting proteins for degradation
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
US9932288B2
(en)
|
2015-12-09 |
2018-04-03 |
West Virginia University |
Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent
|
WO2017156397A1
(en)
|
2016-03-11 |
2017-09-14 |
Board Of Regents, The University Of Texas Sysytem |
Heterocyclic inhibitors of ptpn11
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
SG11201810171SA
(en)
|
2016-05-18 |
2018-12-28 |
Mirati Therapeutics Inc |
Kras g12c inhibitors
|
CN109475531B
(zh)
|
2016-05-31 |
2021-08-17 |
得克萨斯州立大学董事会 |
Ptpn11的杂环抑制剂
|
US10858359B2
(en)
|
2016-06-07 |
2020-12-08 |
Jacobio Pharmaceuticals Co., Ltd. |
Heterocyclic ring derivatives useful as SHP2 inhibitors
|
CN109983001B
(zh)
|
2016-07-12 |
2023-04-04 |
锐新医药公司 |
作为变构shp2抑制剂的2,5-双取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
US11479797B2
(en)
|
2016-10-28 |
2022-10-25 |
Ginkgo Bioworks, Inc. |
Compositions and methods for the production of compounds
|
BR112019009903A2
(pt)
*
|
2016-11-18 |
2019-08-13 |
Neurovive Pharmaceutical Ab |
análogo de sangliferina, combinação, composição farmacêutica, e, método para tratamento de um sujeito sofrendo de câncer ou de malignidade de célula-b
|
CA3047125A1
(en)
|
2016-12-15 |
2018-06-21 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
EP4001269A1
(en)
|
2016-12-22 |
2022-05-25 |
Amgen Inc. |
Benzoisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
US10988766B2
(en)
|
2017-01-06 |
2021-04-27 |
Oregon Health & Science University |
Compositions and methods used in diagnosing and treating colorectal cancer
|
ES2964956T3
(es)
|
2017-01-10 |
2024-04-10 |
Novartis Ag |
Combinación farmacéutica que comprende un inhibidor de ALK y un inhibidor de SHP2
|
TWI820013B
(zh)
|
2017-01-23 |
2023-11-01 |
美商銳新醫藥公司 |
作為別構shp2抑制劑之雙環化合物
|
JP7240320B2
(ja)
|
2017-01-23 |
2023-03-15 |
レヴォリューション・メディスンズ,インコーポレイテッド |
アロステリックshp2阻害剤としてのピリジン化合物
|
JP2020505395A
(ja)
|
2017-01-26 |
2020-02-20 |
アラクセス ファーマ エルエルシー |
縮合n−複素環式化合物およびその使用方法
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
SG11201908820VA
(en)
|
2017-03-23 |
2019-10-30 |
Jacobio Pharmaceuticals Co Ltd |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
CA3058964A1
(en)
|
2017-04-05 |
2018-10-11 |
Revolution Medicines, Inc. |
Methods and reagents for analyzing protein-protein interfaces
|
KR20240033100A
(ko)
|
2017-04-05 |
2024-03-12 |
레볼루션 메디슨즈, 인크. |
협동 결합에 참여하는 화합물 및 그의 용도
|
JP7348071B2
(ja)
|
2017-05-02 |
2023-09-20 |
レヴォリューション・メディスンズ,インコーポレイテッド |
mTOR阻害剤としてのラパマイシン類似体
|
CN110603258A
(zh)
|
2017-05-11 |
2019-12-20 |
阿斯利康(瑞典)有限公司 |
抑制g12c突变型ras蛋白的杂芳基化合物
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
MX2019013954A
(es)
|
2017-05-25 |
2020-08-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras.
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
KR20200051684A
(ko)
|
2017-09-07 |
2020-05-13 |
레볼루션 메디슨즈, 인크. |
암 치료를 위한 shp2 억제제 조성물 및 방법
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
US10435389B2
(en)
|
2017-09-11 |
2019-10-08 |
Krouzon Pharmaccuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
|
ES2944547T3
(es)
|
2017-11-15 |
2023-06-22 |
Mirati Therapeutics Inc |
Inhibidores de KRas G12C
|
TW201938561A
(zh)
|
2017-12-08 |
2019-10-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
AU2019262978B2
(en)
|
2018-05-01 |
2023-07-13 |
Revolution Medicines, Inc. |
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
|
JP7381492B2
(ja)
|
2018-05-01 |
2023-11-15 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Mtor阻害剤としてのc26-連結ラパマイシン類似体
|
EP3788038B1
(en)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
WO2019213526A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
EP3790886B1
(en)
|
2018-05-10 |
2024-06-26 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
WO2019232419A1
(en)
|
2018-06-01 |
2019-12-05 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
US20190375749A1
(en)
|
2018-06-11 |
2019-12-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3807276A2
(en)
|
2018-06-12 |
2021-04-21 |
Amgen Inc. |
Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
KR20210045998A
(ko)
|
2018-08-01 |
2021-04-27 |
아락세스 파마 엘엘씨 |
헤테로사이클릭 스피로 화합물 및 암 치료를 위한 그의 사용 방법
|
AU2019320945C1
(en)
|
2018-08-16 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Fused ring compounds
|
WO2020047192A1
(en)
|
2018-08-31 |
2020-03-05 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
EP3883565A1
(en)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
BR112021012057A2
(pt)
|
2018-12-21 |
2021-10-19 |
Revolution Medicines, Inc. |
Compostos que participam de ligação cooperativa e usos dos mesmos
|
EP4055028A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
MX2022005357A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
AU2020379734A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
JP2023541916A
(ja)
|
2020-09-15 |
2023-10-04 |
レボリューション メディシンズ インコーポレイテッド |
がんの治療における、ras阻害剤としてのインドール誘導体
|